A5011074245- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Adolescent and Pediatric Healthcare
- Vasculitis and related conditions
- Monoclonal and Polyclonal Antibodies Research
- Reproductive System and Pregnancy
- Whipple's Disease and Interleukins
- Systemic Sclerosis and Related Diseases
- Eosinophilic Esophagitis
- Infectious Diseases and Tuberculosis
- Inflammasome and immune disorders
- Urticaria and Related Conditions
- Bone health and treatments
- Pregnancy and Medication Impact
- Bone and Joint Diseases
- Pharmaceutical studies and practices
- Family and Disability Support Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Dermatological and Skeletal Disorders
- Peptidase Inhibition and Analysis
- Autoimmune Bullous Skin Diseases
Centre Hospitalier Universitaire de Poitiers
2010-2021
Université de Poitiers
2013-2018
Hôpital André Mignot
2016-2017
Laboratoire de Génétique Cellulaire
2015
Center for Rheumatology
2013
Institute of Immunology
2013
Centre Hospitalier Universitaire de Nantes
2011
Centre Hospitalier Universitaire de Lille
1995-2010
Hôpital Saint-Philibert
2010
Centre Jean Bernard
2010
One-third of patients with rheumatoid arthritis show inadequate response to tumor necrosis factor α (TNF-α) inhibitors; little guidance on choosing the next treatment exists.To compare efficacy a non-TNF-targeted biologic (non-TNF) vs second anti-TNF drug for insufficient TNF inhibitor.A total 300 (conducted between 2009-2012) arthritis, persistent disease activity (disease score in 28 joints-erythrocyte sedimentation rate [DAS28-ESR] ≥ 3.2 [range, 0-9.3]) and an therapy were included...
Tumour necrosis factor (TNF)-blocker tapering has been proposed for patients with rheumatoid arthritis (RA) in remission.The trial aims to compare the effect of progressive spacing TNF-blocker injections (S-arm) their maintenance (M-arm) established RA study was an 18-month equivalence which included receiving etanercept or adalimumab at stable dose ≥1 year, remission on 28-joint Disease Activity Score (DAS28) ≥6 months and joint damage. Patients were randomised into two arms: by 50% every 3...
Patients treated with tumor necrosis factor-alpha (TNF-alpha) antagonists have an increased risk of infection, but infection due to Legionella pneumophila has rarely been described in patients receiving such therapy.A registry involving 486 clinical departments France was designed by a multidisciplinary group (Recherche Axée sur la Tolérance des Biothérapies [RATIO]) collect data on opportunistic and severe infections occurring TNF-alpha antagonists. All cases are reported RATIO accordance...
Abstract Objective Continuous treatment with the anti–tumor necrosis factor α (anti‐TNFα) antibody infliximab is efficacious in ankylosing spondylitis (AS), whereas discontinuation results disease relapse, variable delay. This study was undertaken to compare efficacy of continuous that a regimen adapted symptom recurrence. Methotrexate (MTX) combination also tested. Methods Patients active AS were randomly assigned at week 0 receive every 6 weeks (continuous treatment) or upon recurrence...
<h3>Introduction</h3> There is a lack of consensus about the definition flare rheumatoid arthritis (RA) and measurement tool. <h3>Objectives</h3> To develop self-administered tool integrating perspectives patient rheumatologist, enabling detection present or recent-past RA flare. <h3>Methods</h3> The perspective was explored by semistructured individual interviews patients with RA. Two health psychologists conducted content analysis to extract items best describing from interviews....
Infliximab, an anti-tumour necrosis factor-α monoclonal antibody, is indicated in rheumatoid arthritis (RA). Our objective was to evaluate the influence of sources infliximab pharmacokinetic variability RA.Eighty-four patients treated with for RA were included a prospective noncomparative study. They analysed between two consecutive infusions. Infliximab concentrations measured before infusion, 2 h, 1 and 4 weeks after infusion immediately next infusion. described using two-compartment...
To assess the efficacy and safety of biologics in a cohort patients with relapsing polychondritis (RP).We conducted French multicentre retrospective study including treated for RP. Efficacy outcomes were clinical response (partial or complete) complete during first 6 months exposure, plus daily corticosteroid dose at months. Other adverse drug reactions (ADRs), persistence factors associated response.This included 41 exposed to 105 (tumour-necrosis factor (TNF) inhibitors, n=60; tocilizumab,...
Objective. Some studies have highlighted the potential benefits of switching from infliximab to etanercept, or after failure one other treatment. To our knowledge, no study has assessed using three anti-TNF-α agents that are currently available. The objective this retrospective was assess response treatment in RA patients who had received agents, namely infliximab, etanercept and adalimumab.
To assess anti-tumour necrosis factor (anti-TNF) agents in patients with refractory systemic rheumatoid vasculitis (SRV).1200 rheumatologists and internists were asked to provide medical files for anti-TNF given as a second-line treatment active SRV cyclophosphamide glucocorticoids.We identified nine cases which drugs SRV, despite previous mean cumulative dose of 8.4 g association high-dose glucocorticoids. The prednisone before therapy was 29.6 mg/day. After 6 months, six remission...
Objectives Little data are available regarding the rate and predicting factors of serious infections in patients with rheumatoid arthritis (RA) treated abatacept (ABA) daily practice. We therefore addressed this issue using real-life from Orencia Rheumatoid Arthritis (ORA) registry. Methods ORA is an independent 5-year prospective registry promoted by French Society Rheumatology that includes RA ABA. At baseline, 3 months, 6 months every or at disease relapse, during 5 years, standardised...
To validate the measurement properties and detection performance of FLARE-RA questionnaire in a longitudinal prospective study.To self-administered questionnaire, we conducted trial rheumatoid arthritis (RA) patients to document: 1) content construct validity by factor analysis, convergent Pearson's correlation with routine assessment patient index data (Routine Assessment Patient Index Data 3 [RAPID-3] questionnaire), RA Impact Disease (RAID) score, Activity Score 28 joints (DAS28), Health...
Anti-TNF-α agents are remarkably effective in the treatment of SpAs. However, 30% patients withdraw from anti-TNF-α yearly because inadequate efficacy or side effects. The objective this study was to assess current practice response a second and third anti-TNF-α.Retrospectively, all records who had received at least two have been studied. For axial forms, considered if 3 months after switching patient favourable expert opinion showed an improvement BASDAI 2 on scale 0-10 50% (BASDAI 50)....
While remission is possible in patients with ankylosing spondylitis (AS), it often unclear what attitude should be adopted once has occurred. We investigated whether dosage adjustment an effective means of maintaining remission.This was a retrospective study drawn from clinical situations. Remission defined using measures [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤ 20/100 and no peripheral joint disease] biological [C-reactive protein (CRP) levels normal value]. The tumor...
Objectives. Pamidronate has recently been used in SAPHO syndrome due to its anti-osteoclastic effect. The aim of this study is determine the usefulness bone remodelling markers for determining efficacy pamidronate treatment.
Objective: To compare the activities of cathepsin B (EC 3.4.22.1) and L 3.4.22.15), calpain 3.4.22.17), dipeptidyl peptidase 3.4.14.5 or DPP IV CD26) in synovial membrane from patients with rheumatoid arthritis (RA), osteoarthritis (OA), post‐traumatic joint injury (PT).
Objective. A functional haplotype of peptidyl arginine deiminase 4 (PADI4) was associated with susceptibility to rheumatoid arthritis (RA) in Asian populations, but the results are contradictory Europeans. We investigated (1) association 2 single-nucleotide polymorphisms (SNP) located exon PADI4 RA another Caucasian population; and (2) between anti-citrullinated protein (anti-CCP) antibodies. Methods. DNA samples were obtained from 405 French patients 275 controls. All met revised criteria...
Objectives To determine when Tropheryma whipplei polymerase chain reaction (PCR) is appropriate in patients evaluated for rheumatological symptoms. Methods In a retrospective observational study done rheumatology units of five hospitals, we assessed the clinical and radiological signs that prompted T. PCR testing between 2010 2014, proportion diagnosed with Whipple's disease, number tests performed diagnoses according to tests, patterns treatments used. Diagnostic ascertainment was based on...
Objective To investigate whether contact with HLA–DR+, but CD80−, fibroblast-like synoviocytes (FLS) in the presence of antigen leads to induction anergy in, rather than stimulation of, T cells. Methods Cell surface expression activation and costimulatory markers on FLS were studied by flow cytometry. Functional changes investigated cell proliferation tuberculin purified protein derivative or allogeneic responses FLS, absence DAP3.B7 cells, a human CD80-transfected mouse fibroblast line....